Sato, Yuki http://orcid.org/0000-0002-7829-7524
Morimoto, Takeshi
Hara, Shigeo
Nagata, Kazuma
Hosoya, Kazutaka
Nakagawa, Atsushi
Tachikawa, Ryo
Tomii, Keisuke
Article History
Received: 9 December 2020
Accepted: 28 January 2021
First Online: 10 February 2021
Declarations
:
: This study was conducted with the approval of the Kobe City Medical Center General Hospital Ethics Committee (No. zn190108).
: Informed consent was not required owing to the retrospective nature of the study.
: Dr. Sato has received lecture fees from Ono Pharmaceutical Co., Ltd. (Osaka, Japan). Dr. Morimoto has received manuscript preparation fees and was on an advisory board of Bristol-Myers Squibb K.K. (Tokyo, Japan). Dr. Hosoya has received lecture fees from Ono Pharmaceutical Co., Ltd. (Osaka, Japan). All remaining authors have no conflicts of interest to declare. We wish to confirm that there are no other known conflicts of interest associated with this publication. Further, there was no significant financial support for this work that could have influenced its outcome.